Table 3 Association of the Pittsburgh sleep quality assessment index (PSQI) with the variables of interest
Linear regression model | |||
|---|---|---|---|
PSQI as a continuous variable | |||
B | 95% CI | P | |
Age (each year) | − .05 | − .20 to .09 | .467 |
Sex (female) | .22 | − .77 to 1.22 | .658 |
Benzodiazepines | 1.44 | .26 to 2.61 | .017 |
Platelet antiaggregants | − 1.84 | − 2.76 to − .92 | .000 |
ACE-inhibitors | − .14 | − 1.25 to .97 | .800 |
Beta-blockers | .27 | − 1.02 to 1.56 | .683 |
Charlson comorbidity Index | .07 | − .13 to .27 | .495 |
Heart failure | .92 | − .16 to 2.00 | .095 |
Albumin (proportion of 1) [%] | − .38 | − 1.11 to .34 | .296 |
Hemoglobin (g/L) [g/dL] | − .12 | − .42 to .19 | .443 |
Metabolic syndrome | − 1.04 | − 2.06 to − .03 | .044 |
Logistic regression model | |||
|---|---|---|---|
PSQI < 5 | |||
OR | 95% CI | P | |
Age (each year) | 1.01 | .91 to 1.12 | .856 |
Sex (female) | 1.03 | .54 to 1.99 | .920 |
Benzodiazepines | .31 | .12 to .80 | .015 |
Platelet antiaggregants | 2.25 | 1.22 to 4.17 | .010 |
ACE-inhibitors | .88 | .47 to 1.67 | .698 |
Beta-blockers | 1.02 | .46 to 2.29 | .953 |
Charlson comorbidity Index | .92 | .80 to 1.07 | .276 |
Heart failure | .49 | .23 to 1.08 | .076 |
Albumin (proportion of 1) [%] | .91 | .85 to .98 | .012 |
Hemoglobin (g/L) [g/dL] | 1.17 | .95 to 1.44 | .139 |
Metabolic syndrome | 2.52 | 1.26 to 5.02 | .009 |
Logistic regression model | |||
|---|---|---|---|
PSQI ≤ 7 | |||
OR | 95% CI | P | |
Age (each year) | .97 | .89 to 1.06 | .536 |
Sex (female) | .60 | .33 to 1.06 | .079 |
Benzodiazepines | .40 | .20 to .81 | .011 |
Platelet antiaggregants | 1.85 | 1.08 to 3.16 | .025 |
ACE-inhibitors | 1.81 | 1.04 to 3.15 | .037 |
Beta-blockers | .93 | .44 to 1.94 | .839 |
Charlson comorbidity Index | .95 | .84 to 1.07 | .424 |
Heart failure | .89 | .47 to 1.66 | .705 |
Albumin (proportion of 1) [%] | .95 | .89 to 1.04 | .069 |
Hemoglobin (g/L) [g/dL] | 1.08 | .90 to 1.30 | .413 |
Metabolic syndrome | 2.11 | 1.11 to 3.40 | .022 |